NPHS1
Nephrin
Also known as: CNF, NPHN, NPHN_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O60500
- Gene
- NPHS1
- Ensembl
- ENSG00000161270
- Chromosome
- 19
- Canonical length
- 1241 aa
- Protein class
- Disease related genes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters
OverviewNCBI Gene
This gene encodes a member of the immunoglobulin family of cell adhesion molecules that functions in the glomerular filtration barrier in the kidney. The gene is primarily expressed in renal tissues, and the protein is a type-1 transmembrane protein found at the slit diaphragm of glomerular podocytes. The slit diaphragm is thought to function as an ultrafilter to exclude albumin and other plasma macromolecules in the formation of urine. Mutations in this gene result in Finnish-type congenital nephrosis 1, characterized by severe proteinuria and loss of the slit diaphragm and foot processes.[provided by RefSeq, Oct 2009]
Canonical amino-acid sequenceUniProt
1241 residues, UniProt reviewed canonical sequence.
>O60500|NPHS1
1 MALGTTLRAS LLLLGLLTEG LAQLAIPASV PRGFWALPEN LTVVEGASVE LRCGVSTPGS
61 AVQWAKDGLL LGPDPRIPGF PRYRLEGDPA RGEFHLHIEA CDLSDDAEYE CQVGRSEMGP
121 ELVSPRVILS ILVPPKLLLL TPEAGTMVTW VAGQEYVVNC VSGDAKPAPD ITILLSGQTI
181 SDISANVNEG SQQKLFTVEA TARVTPRSSD NRQLLVCEAS SPALEAPIKA SFTVNVLFPP
241 GPPVIEWPGL DEGHVRAGQS LELPCVARGG NPLATLQWLK NGQPVSTAWG TEHTQAVARS
301 VLVMTVRPED HGAQLSCEAH NSVSAGTQEH GITLQVTFPP SAIIILGSAS QTENKNVTLS
361 CVSKSSRPRV LLRWWLGWRQ LLPMEETVMD GLHGGHISMS NLTFLARRED NGLTLTCEAF
421 SEAFTKETFK KSLILNVKYP AQKLWIEGPP EGQKLRAGTR VRLVCLAIGG NPEPSLMWYK
481 DSRTVTESRL PQESRRVHLG SVEKSGSTFS RELVLVTGPS DNQAKFTCKA GQLSASTQLA
541 VQFPPTNVTI LANASALRPG DALNLTCVSV SSNPPVNLSW DKEGERLEGV AAPPRRAPFK
601 GSAAARSVLL QVSSRDHGQR VTCRAHSAEL RETVSSFYRL NVLYRPEFLG EQVLVVTAVE
661 QGEALLPVSV SANPAPEAFN WTFRGYRLSP AGGPRHRILS SGALHLWNVT RADDGLYQLH
721 CQNSEGTAEA RLRLDVHYAP TIRALQDPTE VNVGGSVDIV CTVDANPILP GMFNWERLGE
781 DEEDQSLDDM EKISRGPTGR LRIHHAKLAQ AGAYQCIVDN GVAPPARRLL RLVVRFAPQV
841 EHPTPLTKVA AAGDSTSSAT LHCRARGVPN IVFTWTKNGV PLDLQDPRYT EHTYHQGGVH
901 SSLLTIANVS AAQDYALFTC TATNALGSDQ TNIQLVSISR PDPPSGLKVV SLTPHSVGLE
961 WKPGFDGGLP QRFCIRYEAL GTPGFHYVDV VPPQATTFTL TGLQPSTRYR VWLLASNALG
1021 DSGLADKGTQ LPITTPGLHQ PSGEPEDQLP TEPPSGPSGL PLLPVLFALG GLLLLSNASC
1081 VGGVLWQRRL RRLAEGISEK TEAGSEEDRV RNEYEESQWT GERDTQSSTV STTEAEPYYR
1141 SLRDFSPQLP PTQEEVSYSR GFTGEDEDMA FPGHLYDEVE RTYPPSGAWG PLYDEVQMGP
1201 WDLHWPEDTY QDPRGIYDQV AGDLDTLEPD SLPFELRGHL VLocalizationUniProt · AlphaFold · HPA
Whether an antibody against NPHS1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.38
- Highest tissue expression
- 40 nTPM
Expression across tissuesHPA
Tissue
- kidney: 40 nTPM
- pancreas: 22 nTPM
- lymph node: 3.7 nTPM
- tonsil: 2.1 nTPM
- thymus: 0.7 nTPM
- appendix: 0.6 nTPM
Single-cell type
- podocytes: 1,833 nCPM
- pdcs: 255 nCPM
- endometrial secretory cells: 227 nCPM
- endometrial luminal cells: 210 nCPM
- epididymal basal cells: 192 nCPM
- retinal bipolar cells: 145 nCPM
Immune cell
- neutrophil: 0.4 nTPM
- basophil: 0.2 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
Brain region
- cerebral cortex: 2.8 nTPM
- cerebellum: 2.5 nTPM
- white matter: 2.2 nTPM
- thalamus: 2.1 nTPM
- pons: 1.9 nTPM
- basal ganglia: 1.8 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about NPHS1.
Disease | AllUniProt
Conditions NPHS1 is implicated in, by any mechanism.
- Nephrotic syndrome 1 (NPHS1) MIM:256300
Disease | GeneticClinVar
467 pathogenic / likely-pathogenic of 2,137 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Finnish congenital nephrotic syndrome
- Nephrotic syndrome
- NPHS1-related disorder
- Focal segmental glomerulosclerosis
- Congenital nephrotic syndrome
Disease | AutoantibodyPubMed
Conditions in which antibodies against NPHS1 are reported. Each links to that disease's full target list.
Showing 3 of 5 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for NPHS1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
73 publications
- Autoantibodies Targeting Nephrin in Podocytopathies.
2024 · N Engl J Med · RCR 42.4 · 216 citations - Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology.
2022 · J Am Soc Nephrol · RCR 29.9 · 320 citations - Anti-slit diaphragm antibodies on kidney biopsy identify pediatric patients with steroid-resistant nephrotic syndrome responsive to second-line immunosuppressants.
2024 · Kidney Int · RCR 11.6 · 57 citations - Anti-nephrin autoantibodies in steroid-resistant nephrotic syndrome may inform treatment strategy.
2025 · Kidney Int · RCR 9.5 · 27 citations - Anti-nephrin antibodies in adult Chinese patients with minimal change disease and primary focal segmental glomerulosclerosis.
2025 · Kidney Int · RCR 8.4 · 22 citations
Show 20 more of 73 total
- Passive transfer of patient-derived anti-nephrin autoantibodies causes a podocytopathy with minimal change lesions.
2025 · J Clin Invest · RCR 8.2 · 24 citations - Anti-nephrin, anti-podocin and anti-Kirrel1 antibodies: biological challenges and clinical implications.
2026 · Nephrol Dial Transplant · RCR 8 · 8 citations - Pre-transplant anti-nephrin antibodies are specific predictors of recurrent diffuse podocytopathy in the kidney allograft.
2024 · Kidney Int · RCR 7.7 · 37 citations - Potential and pitfalls of measuring circulating anti-nephrin autoantibodies in glomerular diseases.
2025 · Clin Kidney J · RCR 5.1 · 14 citations - Evaluation of methodologies in anti-nephrin autoantibody detection.
2025 · Kidney Int · RCR 4.4 · 13 citations - Childhood idiopathic nephrotic syndrome: recent advancements shaping future guidelines.
2025 · Pediatr Nephrol · RCR 4.2 · 10 citations - Anti-nephrin antibodies guide living donor kidney transplantation in a pediatric patient with primary focal segmental glomerular sclerosis.
2025 · Kidney Int · RCR 4.1 · 11 citations - Detailed Pathophysiology of Minimal Change Disease: Insights into Podocyte Dysfunction, Immune Dysregulation, and Genetic Susceptibility.
2024 · Int J Mol Sci · RCR 3.3 · 14 citations - Circulating nephrin autoantibodies and posttransplant recurrence of primary focal segmental glomerulosclerosis.
2022 · Am J Transplant · RCR 2.6 · 27 citations - Detection of Antinephrin Antibodies in Childhood Idiopathic Nephrotic Syndrome.
2025 · Kidney Int Rep · RCR 2.4 · 11 citations - Recurrence of nephrotic syndrome in kidney grafts of patients with congenital nephrotic syndrome of the Finnish type: role of nephrin.
2002 · Transplantation · RCR 2.3 · 104 citations - Reevaluating anti-nephrin autoantibodies by ELISA using human embryonic kidney-derived recombinant extracellular domain of human nephrin.
2025 · Kidney Int · RCR 2 · 6 citations - Revisiting nephrin signaling and its specialized effects on the uniquely adaptable podocyte.
2025 · Biochem J · RCR 1.9 · 5 citations - Cdc42 Activation in Antinephrin Antibody-Induced Nephropathy.
2025 · J Am Soc Nephrol · RCR 1.9 · 5 citations - Anti-nephrin autoantibodies: novel predictors of post-transplant recurrence of focal segmental glomerular sclerosis.
2024 · Kidney Int · RCR 1.9 · 5 citations - Review of the Role of Rituximab in the Management of Adult Minimal Change Disease and Immune-Mediated Focal and Segmental Glomerulosclerosis.
2023 · Glomerular Dis · RCR 1.8 · 14 citations - Congenital nephrotic syndrome and recurrence of proteinuria after renal transplantation.
2014 · Pediatr Nephrol · RCR 1.6 · 48 citations - Anti-nephrin autoantibodies: a paradigm shift in podocytopathies.
2024 · Nat Rev Nephrol · RCR 1.6 · 11 citations - Autoantibodies Targeting Nephrin in Podocytopathies. Reply.
2024 · N Engl J Med · RCR 1.5 · 7 citations - Clinical Characteristics of Nephrin Autoantibody-Positive Minimal Change Disease in Older Adults.
2024 · Kidney Int Rep · RCR 1.2 · 6 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.7
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.41
- DepMap mean gene effect
- -0.12
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cell-cell adhesion
- gene expression
- glomerular basement membrane development
- JNK cascade
- myoblast fusion
- podocyte development
- positive regulation of actin filament polymerization
- protein localization to synapse
- skeletal muscle tissue development
- slit diaphragm assembly
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Immunoglobulin subtype 2
- Immunoglobulin domain subtype
- Fibronectin type III
- Immunoglobulin-like domain
- Immunoglobulin I-set
- Immunoglobulin V-set domain
- CD80-like, immunoglobulin C2-set
- Immunoglobulin-like fold
- Fibronectin type III superfamily
- Immunoglobulin-like domain superfamily
- Cellular adhesion and signaling domain-containing protein
- Fibronectin type III domain
- Immunoglobulin I-set domain
- Immunoglobulin V-set domain
- CD80-like C2-set immunoglobulin domain
- Immunoglobulin domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of NPHS1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads NPHS1 as an antibody target. Whether an autoantibody or antibody against NPHS1 could matter depends on whether native NPHS1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
NPHS1 is annotated at the cell surface, where native NPHS1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label NPHS1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...